Alopecia areata

Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer

Retrieved on: 
Thursday, March 28, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, IL-17A, Administration, Ulcerative colitis, Congress, Thymic stromal lymphopoietin, Atopic dermatitis, Alopecia areata, Inflammation, Chronic obstructive pulmonary disease, Allergy, TSLP, BCA, CMC, G&A, Interleukin 7, Benaroya Research Institute, Business analyst, Abstract, Asthma, IL-7, Research and development, Drug development, Senior management, BAFF, Eli Lilly and Company, Translational medicine, Autoimmunity, Management

Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.

Key Points: 
  • Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”) a clinical-stage immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2023 financial results and recent business highlights.
  • The Company has also announced the appointment of Robert Lisicki as Chief Executive Officer (CEO), effective April 8, 2024, succeeding its Founding CEO, Someit Sidhu, M.D.
  • Mr. Lisicki joined Zura Bio in January 2024 as President and Chief Operating Officer.
  • Dr. Sidhu continued, "On behalf of the Management Team and Board, I am pleased to welcome Robert as the Chief Executive Officer.

Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights

Retrieved on: 
Monday, March 25, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Itolizumab, Organic acid, Harvard Medical School, Exercise, Alopecia areata, ASN, Partnership, Patient, Gastrointestinal tract, ACR, IL-9, Acquisition, G&A, MPA, Dermatology, Investment, MPH, Therapy, Eosinophilic esophagitis, Retirement, Inflammatory bowel disease, Lupus nephritis, JAK, Pharmaceutical industry

Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights.

Key Points: 
  • Equillium , Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the fourth quarter and full year 2023, as well as corporate and clinical highlights.
  • Research and development (R&D) expenses for the fourth quarter of 2023 were $9.2 million, compared with $8.5 million for the same period in 2022.
  • General and administrative (G&A) expenses for the fourth quarter of 2023 were $3.2 million, compared with $5.2 million for the same period in 2022.
  • Net cash used in operating activities in the fourth quarter was $5.7 million.

STRATA Skin Sciences Announces Initiative to Expand Treatment Coverage

Retrieved on: 
Thursday, March 7, 2024
Lichen planus, Light therapy, Assistant, Vitiligo, Marketing, Cutaneous T-cell lymphoma, Quality of life, Senate, Atopic dermatitis, Skin, CTCL, Mycosis fungoides, CPT, Human, Light, Alopecia areata, Patient, STRATA, SSKN, Insurance, Pharmaceutical industry

The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement rates.

Key Points: 
  • The Company is leveraging its extensive patient database and engaging in targeted governmental relations efforts, this initiative focuses on broadening Current Procedural Terminology (“CPT”) code coverage to increase patient access to advanced treatments and enable higher provider reimbursement rates.
  • “Our focus extends beyond merely seeking expanded insurance coverage; we're advocating for the enhancement of patient quality of life and ensuring access to essential dermatologic treatments," stated Dr. Dolev Rafaeli, Vice Chairman and Chief Executive Officer of STRATA.
  • Over the past two months, as part of this advocacy initiative STRATA has sent over 1,000 legislative support letters to congressional and senate delegates on behalf of its patients.
  • Phototherapy has been the cornerstone of therapy for decades and remains an indispensable part of current therapy.

ASLAN Pharmaceuticals Receives Favorable Opinion From the European Patent Office on Composition of Matter Patent Application for Farudodstat

Retrieved on: 
Thursday, February 29, 2024
SAN, EPO, Composition, Alopecia areata, Patent, Patient, International Examiner, DHODH, ASLN, European Patent Convention, Pharmaceutical industry

Farudodstat is a potent, oral dihydroorotate dehydrogenase (DHODH) inhibitor with the potential to be a first-in-class treatment option for alopecia areata (AA).

Key Points: 
  • Farudodstat is a potent, oral dihydroorotate dehydrogenase (DHODH) inhibitor with the potential to be a first-in-class treatment option for alopecia areata (AA).
  • ASLAN is currently conducting a Phase 2a proof-of-concept trial in AA (the “FAST-AA Study”) and an interim readout from the study is expected mid-2024.
  • “We are very pleased to have received a positive preliminary opinion from the EPO on the Composition of Matter patent application for farudodstat, and recognition that all of our claims were novel and inventive.
  • If granted in the national stages, the new patent will extend the patent protection on farudodstat until at least 2043.

HUTCHMED Reports 2023 Full Year Results and Provides Business Updates

Retrieved on: 
Wednesday, February 28, 2024
Neoplasm, RMB, SHPL, Net, EZH2, Growth, FC, Tax, Follicular lymphoma, FX, Fast Track, TCFD, Ethics, Marketing, RCC, Health, CER, Sintilimab, ITP, Disclosure, Plasma protein binding, Lancet, MET, Completeness, D-19, Paclitaxel, Met, NDA, NSCLC, EGFR, NRDL, Atopic dermatitis, ESG, CRC, PD-1, Completion, Phases of clinical research, Task force, Half-life, Chills, Potential, Breakthrough therapy, NMPA, Investment, FGFR, Research, PFS, AstraZeneca, EMA, ADS, Annual report, ASCO, FDA, Carbon accounting, VEGFR, Lung, COVID-19, Alopecia areata, PMDA, Lilly, Patient, Cancer, Pharmaceutical industry

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Feb. 28, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (Nasdaq/AIM:​HCM; HKEX:​13), the innovative, commercial-stage biopharmaceutical company, today reports its financial results for the year ended December 31, 2023 and provides updates on key clinical and commercial developments. HUTCHMED to host results call and webcasts today at 7:30 a.m. EST / 12:30 p.m. GMT / 8:30 p.m. HKT in English, and at 8:30 a.m. HKT in Chinese (Putonghua) on Thursday, February 29, 2024.

Key Points: 
  • HUTCHMED is committed to progressively embedding sustainability into all aspects of our operations and creating long-term value for our stakeholders.
  • The 2023 Sustainability Report will be published alongside our 2023 Annual Report in April 2024 and will include further information on HUTCHMED sustainability initiatives and their performance.
  • Net Income attributable to HUTCHMED for 2023 was $100.8 million compared to Net Loss attributable to HUTCHMED of $360.8 million in 2022.
  • The net income attributable to HUTCHMED in 2023 was $0.12 per ordinary share / $0.59 per ADS49, compared to net loss attributable to HUTCHMED of $0.43 per ordinary share / $2.13 per ADS in 2022.

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 27, 2024
Janus, Acquisition, Week, Psoriasis, GTN, Research, Health Canada, Investment, Inflammation, FDA, Marketing, Atopic dermatitis, Food, Dermatitis, Growth, Shanda, Patent, JAK1, PDUFA, Pharmacy benefit management, PDE4, Alopecia areata, Food and Drug Administration, Webcast, Half-life, Disease, SLR, Itch, NDA, Prescription, Scalp, Pharmaceutical industry

The Company saw significant GTN improvement in the fourth quarter compared to the GTN in the third quarter, and anticipates further GTN improvement in 2024.

Key Points: 
  • The Company saw significant GTN improvement in the fourth quarter compared to the GTN in the third quarter, and anticipates further GTN improvement in 2024.
  • Total revenues for the quarter ended December 31, 2023 were $13.5 million compared to $3.0 million for the corresponding period in 2022.
  • Net cash used in operating activities was $56.2 during the fourth quarter and $247.1 million during the full year 2023.
  • Arcutis management will host a conference call and webcast today at 8:30 am ET to discuss the financial results for the quarter and year and provide a business update.

An Invitation to Innovaderm’s 5th Breakfast Event, This Year’s Focus is on Alopecia Areata (AA)

Retrieved on: 
Thursday, February 22, 2024
General Health, Health, Clinical Trials, Practice Management, Breakfast, Alopecia areata, Research, Biotechnology, Dermatology, Internet, Skin, AA, AAD, Patient, American Academy

This year, the event will focus on the world of Alopecia Areata (AA).

Key Points: 
  • This year, the event will focus on the world of Alopecia Areata (AA).
  • They will be sharing thoughts on “Clinical Evaluations and Current Treatments for AA” and “Experimental and Future Treatments of AA” respectively.
  • The Breakfast Event will serve as a platform to engage in insightful discussions and network with industry professionals, clinicians, and peers in dermatology clinical research.
  • If you plan to attend AAD in San Diego, we highly recommend reserving your place at our Breakfast Event without further ado.

Patient-Reported Outcomes Data from Longest Running Dermatology Study: TARGET-DERM AA Poster Presented at American Academy of Dermatology (AAD) 2024

Retrieved on: 
Friday, March 8, 2024
Alopecia areata, Anxiety, Natural history, Psoriasis, Autoimmune disease, Professor, Assistant, Hair loss, Quality of life, Atopic dermatitis, Alopecia totalis, Skin, Mental, Entrepreneurship, RWE, Hashimoto's thyroiditis, AA, AAD, Vitiligo, University, Hidradenitis suppurativa, Patient, Disease, Dermatitis, Diagnosis, Social stigma, Depression, Nursing

DURHAM, N.C., March 8, 2024 /PRNewswire/ -- New patient-reported outcomes data presented at AAD 2024 from Target RWE's TARGET-DERM AA registry confirms the high unmet need and significant disease burden in patients with moderate to severe alopecia areata (AA). TARGET-DERM is the largest and most comprehensive longitudinal RWE study observing patients with immune-mediated inflammatory skin conditions in the United States.

Key Points: 
  • Patients with AA have a high unmet medical need due to comorbid conditions and high impact on quality of life.
  • The most common comorbid conditions associated with AA include vitiligo, atopic dermatitis (eczema), Hashimoto's thyroiditis, psoriasis, and systemic lupus erythematosus.
  • TARGET-DERM AA is distinctively positioned to address real-world access to care, disease progression, diagnosis, and treatment in patients with moderate to severe AA.
  • "What's important about our data presented at AAD and TARGET-DERM AA is that we are gaining insights on the impact of the disease.

Arcutis to Report Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Friday, February 16, 2024
FDA, Atopic dermatitis, Dermatology, Alopecia areata, Scalp, Webcast

ET

Key Points: 
  • ET
    WESTLAKE VILLAGE, Calif., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its fourth quarter and full year financial results and provide a business update on Tuesday, February 27, 2024.
  • Arcutis management will host a conference call and webcast that day at 8:30 a.m.
  • A live webcast of the call and the presentation material will be available on the “ Events ” section of the Company’s investor website.
  • An archived replay of the webcast will be available on the Arcutis investor website following the conference call.

Alys Pharmaceuticals launches with $100M financing from Medicxi to advance Immuno-Dermatology focused pipeline

Retrieved on: 
Monday, February 12, 2024
Cancer, Cutaneous T-cell lymphoma, Research, Skin, POC, University of Massachusetts, Atopic dermatitis, Inflammation, Gustave Roussy, Vitiligo, Mastocytosis, Partner, Peptide, Alopecia areata, Therapy, Patient, Small RNA, LMU, Georgia Tech, Nobel Prize, Pharmaceutical industry

BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.

Key Points: 
  • BOSTON and GENEVA, Switzerland, Feb. 12, 2024 /PRNewswire/ -- Alys Pharmaceuticals, Inc. ("Alys"), an immuno-dermatology focused company, launches today with an R&D pipeline enabled by multiple platform technologies and a $100 million financing by Medicxi.
  • Originating from the aggregation of six asset-centric Medicxi companies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications.
  • The pipeline also includes programs focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma or prevention of skin side effects of oncology therapies.
  • Alys combines the assets and platforms of Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics.